Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CLL1-CD33-NKG2D Bicephali CAR-T Cells in Relapsed/Refractory AML
NCT07370064Phase 2Not yet recruiting
- Sponsor
- Xuzhou Medical University
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of anti-CLL1-CD33-NKG2D bicephalic CAR-T cells in acute myeloid leukemia (AML), sponsored by Xuzhou Medical University. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
anti-CLL1-CD33-NKG2D bicephalic CAR-T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07370064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07370064.